Michigan businesses brace for change after Trump signs executive order to reclassify marijuana

President Trump signed an executive order reclassifying marijuana from Schedule I to Schedule III, which administration and industry sources say will ease research barriers and could materially change federal tax treatment for cannabis firms by alleviating constraints tied to IRC Section 280E. Michigan operators expect improved ability to deduct standard business expenses and greater pharmaceutical interest in standardized cannabis products, but a newly proposed 24% state tax introduces uncertainty for margins and pricing heading into 2026. Overall the move is likely constructive for cannabis-sector fundamentals and investor interest, while state-level tax actions may partially offset upside for local operators.

Analysis

Market structure: Federal rescheduling to Schedule III materially favors US multi-state operators (MSOs), pharma partners and cannabis REITs by unlocking R&D, federal tax deductions (potential margin expansion ~300–800 bps) and easier capital access over 6–24 months. Retail operators in high-tax states (Michigan’s new 24% levy) and commodity-focused Canadian LPs face margin compression and demand elasticity risk as consumers trade down or revert to illicit channels.

Risk assessment: Tail risks include a legal challenge or reversal by a future administration (plausible 20–30% within 2 years), IRS delay on 280E guidance (0–12 months) and unchanged banking rules absent Treasury/FDIC action. Hidden dependencies: effective benefit hinges on IRS/DEA rule-making, FDA/pharma partnerships and banks’ willingness to onboard MSOs; catalysts are IRS 280E guidance (30–90 days), DOJ/DEA implementation (60–180 days) and first pharma licensing deals (6–12 months).

Trade implications: Near-term (days–weeks) expect a spec pop in US-listed MSOs; medium-term (3–12 months) favors selective longs in profitable US MSOs (TRUL, CURLF, GTBIF) and cannabis real-estate (IIPR) plus credit tightening for senior MSO bonds (spreads compress 200–400 bps). Use defined-risk option structures (12-month call spreads) to express upside while capping time decay; avoid Michigan-centric retailers and low-cash Canadian growers without US retail exposure.

Contrarian angles: Consensus underestimates implementation friction—if IRS/FDIC do not act within 90–120 days the initial rally may reverse; Canadian names (TLRY/CGC) may be overbought as market prizes US regulatory change prematurely. Unintended consequences include state tax hikes (Michigan 24%) pushing price elasticity thresholds: >20% retail tax likely reduces legal-channel demand >10% in affected states over 12 months.

Key Decisions for Investors

• Establish a 2–3% long position split between Trulieve (TCNNF) and Curaleaf (CURLF) over next 2–4 weeks; target 30–80% upside in 6–12 months if IRS 280E guidance issued within 90 days; hard stop-loss at -20% from entry.
• Buy 12-month call spreads on TCNNF: buy 25% OTM calls and sell 50% OTM calls (size equivalent to 0.5–1% portfolio exposure) to cap premium and target asymmetric upside if implementation occurs within 6–12 months; close or roll if no IRS guidance in 90 days.
• Initiate a pair trade: long TRUL (2%) / short Tilray (TLRY) (1%) to capture US-facing premium; trim positions if TRUL:TLRY relative performance narrows to <+15% over a 3-month rolling period or if DEA/IRS signals are negative.
• Reduce/avoid exposure to Michigan-centric retail operators and capex-heavy Canadian LPs by 50% immediately; reassess only after seeing (a) state-level consumer demand data over 2 quarters post-tax change and (b) MSO margin improvement >200 bps.
• Conditional allocation trigger: monitor for three binary catalysts—(1) IRS issues 280E guidance within 90 days, (2) two national banks publicly accept MSO deposits within 120 days, (3) first Big Pharma licensing deal announced within 12 months; if two of three occur, increase MSO exposure by +1–2%.